Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study was to investigate the efficacy and safety of pamiparib in patients
with EGFR-TKIs-resistant NSCLC, using a single-center, dual-arm, open-label design.